In translational medicine, researchers indicated that targeting LDHA might be a prospective therapy to enhance radiotherapy effectiveness in NSCLC patients, which needs to be deeply validated by clinical trials [51]. This evidence concerns the gene LDHA and non-small cell lung carcinoma.